Biogen (BIIB) Sɔɔtɔ Fɔrɛkɛst
Nɔnyɔ nyɛ$227.93Nɔɔ 25 Gbo 2026 19:59 UTC
Nyuɛ+0.69%
AI forecast: BIIB
AI bɔɔ target price fɔ trading day tɛnɛ, week ɛnɛ ɛkpɔ month ɛnɛ ɛkɛ. Change bɔɔ latest price lɛ. Statistical estimates lɛ, not investment advice.
Nɔnyɔ ɔhɛ 6 dɛnɛ a akɛ
Premium shows the AI's price targets for 1 day, 1 week and 1 month for this and every other stock.
Unlock Premium🔒 Nɔ nyɛmɛ nyɛ nyɛmɛ
The forecast track record — every past forecast next to the actual close — is part of Premium.
Unlock PremiumƐŋɛ Nɛ Kɔmpɔni A
Biogen Inc. develops, manufactures, and commercializes therapies with a focus on neurology, oncology, and immunology. The company’s products are designed to treat conditions such as multiple sclerosis, non-Hodgkin lymphoma, rheumatoid arthritis, Crohn’s disease, and psoriasis.
